MPNSTs are aggressive, metastatic, nerve-associated tumors that occur sporadically (~50% of cases) or in association with the inherited syndrome neurofibromatosis type 1 (NF1) 1 . The lifetime risk of developing sporadic MPNST is 0.001%, compared to 5-13% for NF1 (1 in 3,000 people), with MPNSTs often arising from pre-existing plexiform neurofibromas 1,2 . Despite advances in understanding MPNST biology, the primary treatment of MPNSTs, regardless of origin, is tumor resection followed by radiation and the administration of nonspecific chemotherapeutic agents, a regimen that resulting in 5-year survival rates of less than 25% in patients with metastatic disease 3-6 . The most commonly altered gene known to cause benign neurofibroma formation and further progression to MPNST is NF1, which encodes neurofibromin 1, a RAS GTPase-activating protein that causes NF1 syndrome when mutated 7-10 . NF1 mutation causes increased and aberrant signaling through pathways promoting cell growth and proliferation (RAS-mitogen-activated protein kinase-extracellular sginal-regulated kinase (RAS-MAPK-ERK) and phosphatidyl inositol 3-kinase (PI3K)-AKT-mTOR) in human neurofibromas and MPNST-derived cell lines [11] [12] [13] . Overexpression of growth factor receptors and ligands such as EGFR, NRG, PDGF, HGF, SCF and TGFB1 are also observed in neurofibromas and MPNSTs with NF1 mutation [14] [15] [16] [17] [18] [19] . Besides NF1 mutations, genomic aberrations have not been identified in neurofibromas. However, genomic aberrations including deletions and/or mutations of cell cycle regulators (TP53, RB1 and CDKN2A), gene amplification of growth factor receptors (ERBB2, EGFR, KIT, MET and PDGFR) and the presence of hyperdiploid or near-triploid genomes commonly occur in human MPNSTs 14-33 . These observations suggest that progression to malignancy requires many cooperating genomic alterations. High levels of genomic complexity make the identification of human MPNST genetic drivers difficult, and it remains unresolved (i) what gene(s) cooperate with NF1 loss in MPNST formation, (ii) what additional gene modules cooperate in MPNST formation, (iii) what epigenetic alterations drive MPNST formation and (iv) what genes and signatures are involved in the maintenance of MPNST. Although some genes and genetic pathways are implicated in MPNST development, there are still many left to uncover to create effective therapies for the treatment of MPNST in humans.
RESULTS

SB-accelerated neurofibroma and MPNST formation
Four experimental mouse cohorts underwent SB-induced mutagenesis on wild-type or tumor-predisposing backgrounds after Cnp-cre induction in Schwann cells and their precursors ( Supplementary  Fig. 1a ) 35, 38, 41, 42 . Mice lacking all components for SB mutagenesis served as controls. The Cnp-EGFR (hereafter called EGFRoverexpressing) and Cnp-cre; Cnp-EGFR; Trp53 R270H (hereafter called EGFR-overexpressing and p53-mutant) mice with or without SB mutagenesis predominatly developed nerve-associated tumors throughout the body ( Supplementary Fig. 1b and Supplementary  Table 1 ). Nerve-associated tumors had histological features corresponding to Schwann cell tumor stages: Schwann cell hyperplasia, benign grade 1 PNSTs (neurofibromas) and aggressive grade 3 PNSTs (MPNST in humans) ( Supplmentary Fig. 1c,d) . Mouse grade 3 PNSTs developed in anatomical regions corresponding to those observed for human MPNSTs (Supplementary Fig. 2a,b) 6, 43, 44 . Moreover, some control and SB-derived grade 3 PNSTs contained regions of divergent cellular histological subtypes and differentiation events characteristic of some human MPNSTs (Supplementary Fig. 3a,b) [45] [46] [47] . Neurofibromas showed no divergent differentiation. Collectively, our mouse model data indicate that the common genetic changes in human MPNST produce a phenotype in mice that resembles the human disease.
To determine whether SB-induced mutagenesis accelerated tumor formation, SB expression and activity in neurofibromas and grade 3 PNSTs were first confirmed by immunohistochemistry and PCR excision assay, respectively ( Supplementary Fig. 1e ) 48 . Wild-type or p53-mutant mice undergoing transposition developed few Schwann cell tumors (~2-7%; Fig. 1a ). As previously reported, EGFRoverexpressing mice developed nerve hyperplasia with low incidence of neurofibroma formation (~17%) and no grade 3 PNST formation ( Fig. 1a) 41 . In contrast, SB mutagenesis significantly enhanced neurofibroma formation (~35%; P = 0.0155) and induced grade 3 PNST formation (~9.2%; P = 0.0141) in EGFR-over expressing mice. EGFR-overexpressing and p53-mutant transgenes cooperated to significantly increase neurofibroma and grade 3 PNST formation (P < 0.0001; Fig. 1a ). SB-induced mutagenesis in the context of both tumor-predisposing alleles led to neurofibroma development, significantly increased grade 3 PNST incidence (P = 0.0005) and significantly reduced grade 3 PNST-free survival compared to mice with both tumor-predisposing alleles alone (P < 0.0001; Fig. 1b ). Tumor penetrance for each genotype is summarized in Supplementary  Table 1 . Overall, SB-induced mutagenesis increased grade 3 PNST incidence compared to controls.
Identification of Schwann cell tumor driver mutations
T2/Onc transposon insertion sites from 269 SB-derived neurofibromas and 106 SB-derived grade 3 PNSTs from 100 SB-and T2/Oncmutagenized mice were analyzed to identify driver mutations (CISs). We used two statistical methods to identify CISs: TAPDANCE and Gene-centric CIS analyses (see Online Methods for details; Table 1 , Supplementary Table 2 and Supplementary Data 1 and 2) 49, 50 . TAPDANCE analysis identified 511 neurofibroma and 34 grade 3 PNST driver mutations, with 21 genes overlapping. Genecentric CIS analysis identified 535 neurofibroma and 75 grade 3 PNST driver mutations, with 32 genes overlapping. Taking into account coinciding CISs from each analysis, we identified 87 grade 3 PNST (25.3% overlap) and 695 neurofibroma (50.1% overlap) driver mutations, with 37 genes common to both tumor types.
Analysis of the association of TAPDANCE-identified CISs with tumor type identified significant driver mutations in neurofibromas (n = 47) and grade 3 PNSTs (n = 10) ( Table 1 , Supplementary  Fig. 4a,b and Supplementary Table 2 ). Known Schwann cell tumor suppressor genes Nf1 and Pten were significantly associated with grade 3 PNSTs and were identified in 34.9% (P = 8.04 × 10 −6 ) and 30.2% (P = 3.85 × 10 −6 ) of tumors, respectively 13, 51 . In neurofibromas, insertions in Nf1 and Pten contributed to 16.4% and 14.1% of tumors, respectively. The most commonly mutated neurofibroma CISs were in Csmd1 (46.8%; P = 1.12 × 10 −5 ), Utrn (30.5%; P = 0.02189) and Zbtb20 (29.4%; P = 1.15 × 10 −5 ). The orthologs of genes previously implicated in human MPNST formation were also identified, including Bmpr2 (9.4%; P = 0.005), Jak2 (5.7%; P = 0.0013) and Nf2 (5.7%; P = 0.0013). 
A r t i c l e s
The position and orientation of the T2/Onc murine stem cell virus (MSCV) promoter relative to the direction of gene transcription can be used to predict whether T2/Onc is likely to drive or disrupt gene transcription 52 . Transcriptional activation may occur if the majority of transposon insertions are orientated upstream of a gene or translational start site with MSCV promoters in the same direction as gene transcription; the gene in this situation would be considered a putative proto-oncogene (for example, Eras, Foxr2 and Zfp521) ( Supplementary Fig. 5a and Supplementary Table 3 ). Disruption of transcription may occur if the transposons land in a gene with no MSCV promoter orientation or insertion site bias within the locus; in this situation, the gene would be a putative tumor suppressor gene (for example, Nf1 and Pten) ( Supplementary Fig. 5b and Supplementary Table 3 ). Twenty putative proto-oncogenes and 67 putative tumor suppressor genes were identified in grade 3 PNST CISs ( Table 1 and Supplementary Table 3 ).
Comparative analysis of grade 3 PNST CISs
The relevance of the CIS-associated genes to human MPNST formation was evaluated by cross-species comparative analysis of the grade 3 PNST CISs to previously generated human array-comparative genomic hybridization (aCGH), SNP array, human microarray expression and methylome data from normal Schwann cells, neurofibromas and MPNSTs ( Fig. 2) 5, 53, 54 . Using human MPNST aCGH data, we identified CISs corresponding to human genes with a tendency for copy number alteration (CNA) gains (n = 31; ZBTB10, CDK13, RAB2A, SHFM1 and CPNE3) and losses (n = 34; CDKN2A, JAK2, NF1, NF2, FAF1, PLAA and PICALM) ( Fig. 2, Supplementary Figs. 6  and 7 and Supplementary Table 4 ) 54 . Comparably, whole-genome SNP analysis on additional MPNSTs (n = 14) identified several CISs corrresponding ot human genes in chromosomal regions that were gained (BMPR2, CPNE3 and EML4) and lost (CDKN2A, JAK2 and PLAA) in >35% of the samples ( Supplementary Table 5 ). However, many recurrently gained or lost genes were found in regions of large 
CISs were identified by the TAPDANCE and Gene-centric CIS methods. Twenty-two CISs were identified by both statistical analyses independently. P values and q values were calculated as described by Sarver et al. 49 and Brett et al. 50 . Prediction on gene function indicates whether the T2/Onc insertion would cause transcriptional activation of a gene (drives and drives N-terminal truncation) or would disrupt gene transcription (disrupts) on the basis of the position and orientation of the T2/Onc insertion relative to gene transcription.
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A r t i c l e s chromosomal rearrangement, making it difficult to discern whether they are driver or passenger mutations. To address this concern, methylome and microarray expression data from human Schwann cell tumors were analyzed. Promoter CpG island shore methylation status is predictive of gene expression: hypermethylation is associated with gene silencing, and hypomethylation is associated with gene expression 53 . We used MPNST whole-methylome data to analyze the methylation patterns of promoter CpG island shores 53 . Fifty-five human genes corresponding to CISs showed significant differential hypo-or hypermethylation patterns in their CpG island shores ( Fig. 2 , Online Methods and Supplementary Table 6 ). Six human genes corresponding to CISs showed hypomethylation in >10% of tumors (BMPR2, PRDX1, PTPN14, BAZ1B, JMY and MAEA), whereas only KLF13 was hypermethylated in >10% of MPNSTs.
To assess the impact of CNAs and methylation patterns on gene expression, we used microarray expression data. Seventy-seven CISs had a human ortholog on the microarray (Supplementary Fig. 8 ) 5 . Microarray expression data predicted genes corresponding to CISs that were either upregulated (EIF4ENIF1, EML4, PTCH1, TRIP10, ZBTB10, ZNF217 and ZNF521) or downregulated (TAOK1, PICALM, NF1, NF2, SPAG9, SRGAP2 and PTEN) in disease progression to MPNST ( Fig. 2 and Supplementary Fig. 8) . Overall, genes we predicted to be oncogenes from the SB screen showed the expected biases in overexpression, CNA gain and hypomethylation in human MPNSTs relative to controls, and genes were predicted to be tumor suppressor genes if they showed reductions in gene expression, CNA loss and hypermethylation ( Fig. 2) . These genes included known drivers of MPNST formation (CDKN2A, PTEN and NF1) and new candidate drivers (BAZ1B, FOXR2, ERAS, PLAA, DIP2C and PICALM).
Lastly, we used the Catalog of Somatic Mutations in Cancer (COSMIC-v63) database to assess alterations in genes corresponding to CISs in other human cancers ( Supplementary Table 7 ) 55 . Human genes corresponding to the grade 3 PNST CIS list are significantly enriched for alterations in the Cancer Gene Census (12/488 genes, Fisher's exact test P = 2.99 × 10 −6 ; hypergeometric test P = 3.21 × 10 −6 ), indicating that we identified driver mutations common to many cancer types. . 8 ), and genes that are upregulated are shown in magenta (a), genes that are downregulated are shown in blue (b), and those with no change or that have no probes on the microarray are shown in gray (c). To identify recurrent CNAs, we considered each gene that showed a gain (or loss) pattern, if the ratio of gain (or loss) out of all 51 cases was more than 1.5× the ratio of loss (or gain). Significant recurrent CNAs had to be observed in 23 of 51 samples (95th percentile). (Fig. 3a) 51, [56] [57] [58] . Seven CISs (Bmpr2, Crebbp, Dyrk1a, Mark2, Mycn, Ppp2r2a and Pten) are involved in signaling through all three pathways as canonical members and/or effectors.
MPNST CIS genes are enriched in signaling pathways
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Co-occurring CISs in grade 3 PNSTs
Co-occurrence analysis was performed to identify genes frequently mutated together in grade 3 PNSTs at a higher frequency than expected by chance 49 . Co-occurrence analysis of the 34 TAPDANCE CISs identified 99 pairs of co-occurring CISs (Supplementary Table 10) .
Several genes were identified as CISs that co-occured with the known MPNST driver Nf1: Pten, Dyrk1a, Ppp6r3, Taok1, Picalm, Top2b, Srgap2 and Ccny (Fig. 3b and Supplementary Table 10 ). Nf1 and Pten were present in the highest percentage of tumors as single CISs (34.9% and 30.2%, respectively; Table 1 ) and co-occurred in 13 of 106 grade 3 PNSTs (Fisher's exact test P = 7.05 × 10 −5 ) but in only 1 of 269 neurofibromas (Fig. 4a) . Human microarray expression data demonstrated a reduction in NF1 and PTEN levels with disease progression to MPNST (Supplementary Fig. 8) . These data suggest that co-occurring mutations in Nf1 and Pten cooperate in the development of grade 3 PNSTs and corresponding mutations in the human genes may cooperate in human MPNST progression.
To address whether Nf1 and Pten mutations cooperate to form Schwann cell tumors in vivo, we generated transgenic mice with biallelic inactivation of Nf1 and heterozygous loss of Pten in cells expressing Cnp-cre. Cnp-cre; Nf1 fl/fl ; Pten fl/+ mice had a significantly decreased median survival time of 101 d compared to those of control Cnp-cre; Nf1 fl/fl (185 d; log-rank P = 0.017) and Cnp-cre; Pten fl/+ (323 d; log-rank P < 0.0001) mice (Fig. 4b) . Cnp-cre; Nf1 fl/fl ; Pten fl/+ mice (n = 5) succumbed to paralysis-related deaths with peripheral nerve hyperplasia and tumors, the majority of which were grade 1 neurofibromas (Fig. 4c) . Notably, grade 1 neurofibromas in the extremities (sciatic nerve and brachial plexus) contained regions of high-grade PNST histology (Fig. 4d) . Cnp-cre; Nf1 fl/fl mice (n = 4) developed nerve hyperplasia and neurofibromas but no high-grade PNSTs. Cnp-Cre; Pten fl/+ mice (n = 15) developed hematopoietic malignancies rather than Schwann cell-related phenotypes.
These data are consistent with the results of our previous experiments in which Dhh-cre; Nf1 fl/fl ; Pten fl/+ mice only developed neurofibromas, whereas Cnp-cre; Nf1 fl/fl ; Pten fl/+ mice had a shorter median survival time and possessed regions of high-grade PNST development 59 . Both mouse models demonstrate the manner in which Nf1 and Pten mutations cooperate in accelerating Schwann cell tumorigenesis. Additional cooperating mutations identified in the co-occurrence analysis may provide insight into cooperating signaling pathways that promote MPNST formation in humans.
FOXR2 has a role in human MPNST maintenance
Foxr2 is a grade 3 PNST CIS that is predicted to be a proto-oncogene, owing to the orientation and position of T2/Onc insertions (Fig. 5a) . mRNA fusion transcripts of the T2/Onc MSCV promoter/splice donor and Foxr2 were identified in tumors with T2/Onc insertions in the Foxr2 locus (Fig. 5b) . The sequenced products showed splicing from the T2/Onc splice donor to each exon of the Foxr2 gene, including to a cryptic exon not previously annotated in intron 2 (labeled exon 2´) ( Fig. 5a,b) . T2/Onc fusion transcripts led to increased Foxr2 mRNA and protein expression in tumors and tumor-derived cell lines, suggesting that Foxr2 functions as a proto-oncogene ( Fig. 5c-e) . Immunohistochemical analysis of a human tissue microarray (TMA) demonstrated higher cytoplasmic FOXR2 expression in MPNSTs than in neurofibromas (Fig. 6a,b) . FOXR2 mRNA and protein levels were higher in MPNST cell lines than in normal Schwann cells and CDK4and TERT-immortalized human Schwann cells (iHSCs) (Fig. 6c) 59 . MPNST cell lines also had cytoplasmic FOXR2 expression ( Fig. 6d) .
FOXR2 is a gene with unknown function. To explore the role of FOXR2 in MPNST formation, we developed constructs to overexpress the full-length cDNA or to knockout the gene using transcription activator-like (TAL) effector nucleases (TALENs) ( Supplementary  Fig. 9a,b) in iHSCs and MPNST cell lines 5, 59 . FOXR2 overexpression in the iHSC clone HSC1λ increased total FOXR2 protein and cytoplasmic staining, minimally increased in vitro proliferation and significantly increased soft-agar colony formation (two-tailed t test P < 0.0001) compared to control cells expressing luciferase (Fig. 7a- Supplementary Fig. 10a) . Xenograft experiments showed no tumor formation in the control HSC1λ cells, but 3 of 5 mice harboring FOXR2-overexpressing cells developed a tumor ( Supplementary  Fig. 11a,b) . This phenotype was confirmed by TALEN-mediated targeted knockout of FOXR2 in S462-TY and STS26T human MPNST cell lines (Supplementary Fig. 9b ). TALENs that generated knockout or heterogeneous mutations (called mutation detected) of FOXR2 caused loss of protein, as detected by immunoblot analysis ( Fig. 7d and Supplementary Fig. 9c) . FOXR2 knockout and mutationdetected cell lines had reduced proliferation and significant reductions in colony-forming ability relative to HPRT knockout control cells (Student's t test P < 0.0001) ( Fig. 7e and Supplementary Fig. 10b,c) . Additionally, FOXR2 loss inhibited the ability of STS26T cells to form tumors in xenograft experiments compared to HRPT knockout controls (Fig. 7f) . Fig. 10d,e) . Collectively, FOXR2 has minor effects on proliferation in vitro, whereas effects on anchorage-independent growth and tumorigenicity are more profound.
DISCUSSION
We performed a large forward genetic screen in Schwann cells using SB somatic cell mutagenesis. We identified hundreds of genes that cooperated with EGFR overexpression and loss of p53 function to form neurofibromas and grade 3 PNSTs. Many co-occurring CISs were identified, suggesting that specific, cooperating genetic mutations are required for tumor development. CISs were also identified in known signaling pathways altered in human MPNSTs, including in Wnt/β-catenin, PI3K-AKT-mTOR and growth factor signaling [11] [12] [13] 58 . Lastly, we identified several new proto-oncogenes, including Foxr2, and elucidated a role for FOXR2 in human MPNST maintenance.
SB-induced mutagenesis alone or on the Trp53 R270H background was insufficient for Schwann cell tumorigenesis, in contrast to previous reports in which SB alone caused tumor formation 35, 60 . This may be explained by differences in the number of cells that are susceptible to SB-driven mutagenesis. Compared to colonic epithelial cells, which have a high turnover rate, Schwann cells have a turnover rate that is near zero unless injury occurs 60, 61 . Moreover, SB-mediated mutagenesis is a random event, and mutations that confer selective advantage for clonal outgrowth are rare events. Taken together, these considerations indicate that targeting a small population of cells with a low turnover rate may produce fewer SB-induced tumors unless preexisting mutation(s), such as ones resulting in EGFR overexpression, are present to expand target cell populations 41 .
CIS overlaps between two methods for defining CISs in grade 3 PNSTs and neurofibromas were 65% and 68%, respectively ( Table 1 and Supplementary Table 2 ). The discordance in CIS calling primarily derives from the methods used to identify a CIS 49, 50 . Genecentric CIS analysis uses window sizes corresponding to annotated genes in addition to the 15,000 bp upstream of each to account for the promoter region 50 . Therefore, the number of insertions required for a sequence to be identified as a CIS in this analysis depends on gene size (that is, large genes require many insertions, whereas smaller S462-TY npg A r t i c l e s genes require fewer). TAPDANCE analysis generates random window sizes throughout the genome and does not require gene annotation to identify CISs, reflected by the fact that four 'gene-barren' regions were present in the list of CISs in neurofibroma ( Supplementary  Table 2 ) 49 . These regions could contain important enhancer elements, unannotated genes, noncoding RNAs or other gene regulatory elements. The two methods are complementary and enhance CIS identification.
On the basis of the number of neurofibromas (n = 269) and grade 3 PNSTs (n = 106) sequenced, we conclude that there is a disproportionate number of CISs in neurofibromas (695) and grade 3 PNSTs (87). Analysis of unique transposon insertion site non-redundant regions identified 33,022 and 139,543 non-redundant regions for grade 3 PNSTs and neurofibromas, respectively. This discrepancy can be reconciled by the genetic heterogeneity of the SB-induced tumors. The fewer grade 3 PNST non-redundant regions were sequenced at a higher frequency than the neurofibroma non-redundant regions, suggesting that few cells acquired mutations in strong genetic drivers that conferred a selective advantage for clonal outgrowth. These clonal insertions were sequenced thousands of times more than in the more genetically heterogeneous neurofibromas. Additionally, it is possible that only a few strong driver mutations in Schwann cells are required for progression to grade 3 PNST, whereas there are many alterations that are sufficient to cause neurofibroma formation. For example, cells may accumulate many mutations, but only the right combination of mutations in two or more genes may drive high-grade tumor formation, as we observed in the Nf1-Pten model. Lastly, we can reliably identify low-penetrant CISs with higher statistical power, given the larger neurofibroma sample size compared to that of the grade 3 PNSTs.
CIS analysis identified a disproportionate number of putative tumor suppressor genes compared to proto-oncogenes ( Table 1 and Supplementary Table 2) , and these observations also occurred in other SB screens in solid tumors 34, 60, 62 . These findings can probably be explained in several ways. First, the T2/Onc MSCV promoter is not strong enough to sufficiently transcriptionally activate proto-oncogenes. A body-wide SB screen using the CAGGs promoter instead of the MSCV promoter in T2/Onc identified a larger spectrum of tumors and CISs 35 . Additionally, T2/Onc can insert in both orientations, with less insertional position bias within or near a gene, to cause inactivation, meaning that there is a greater chance of genes being inactivated. Alternatively, for driver oncogenes, we observed a clustering of T2/Onc insertions in promoter regions or 5′ UTRs that are predominantly in orientations that drive transcription.
Comparative genomic analysis reliably identified genes previously implicated in human MPNST formation (such as CDKN2A, NF1 and PTEN) 27, 63 . We also identified new genes that are recurrently overexpressed, have CNA gains and are hypomethylated (BAZ1B, FOXR2 and ERAS) as well as ones that are underexpressed, biallelically inactivated and hypermethylated (DIP2C, PLAA and PICALM) in human MPNSTs (Fig. 2, Supplementary Figs. 6-8 and Supplementary  Tables 4-6 ) 63, 64 . However, we identified genes (for example, ZBTB10 and EML4) with CNA gains in human MPNSTs that were predicted to be disrupted by SB-induced mutagenesis. This discrepancy may reflect differences in mouse and human MPNST formation and/or CNAs observed in human MPNSTs may mask the function of the gene in tumor progression. Additionally, many of the CISs could be categorized into signaling pathways (PI3K-AKT-mTOR, MAPK (ERK, JNK and p38) and Wnt/β-catenin) ( Fig. 3a and Supplementary  Tables 8 and 9) . Collectively, these data identify new genetic drivers and/or signaling pathways that potentially promote human MPNST formation. Further experimental evidence is required to determine the contributions that candidate driver gene(s) and/or pathways have on MPNST development.
Nf1 and Pten were most frequently mutated in our screen, and Pten was significantly mutated together with Nf1 in grade 3 PNSTs. Loss of NF1 alone is not sufficient for MPNST formation in genetically engineered mouse models of Nf1 loss [65] [66] [67] [68] . Monoallelic inactivation of Pten in Schwann cells with activated Kras G12D overexpression caused grade 3 PNST formation 51 . Neither mutation alone was sufficient to cause grade 3 PNSTs. These data suggest that, as with Nf1, Pten mutations alone are insufficient for MPNST formation. Our mouse model of biallelic Nf1 inactivation and Pten heterozygosity demonstrated cooperation of these genes in high-grade PNST formation relative to loss of either allele alone ( Fig. 3a-d) . We attempted to generate biallelic loss of Nf1 and Pten with the Cnp-cre model, but no live mouse originated from the crosses with the expected mendelian ratio of 1:8. The Cnp-cre; Nf1 fl/dl ; Pten fl/fl genotype may be embryonic lethal. However, Nf1 loss in the context of Pten heterozygosity produced tumors with regions containing high-grade PNSTs, a finding that is consistent with the observation that PTEN expression is not completely lost in human MPNSTs. The previously reported Dhh-cre; Nf1 fl/fl ; Pten fl/+ mouse model presented with neurofibromas and required biallelic inactivation of the second Pten allele for highgrade PNST formation 59 . Therefore, it is important to consider gene dosage, the co-occurrence of mutations and the timing of mutation induction in determining effective mouse models for developmental and therapeutic studies.
FOXR2 is a forkhead-box (FOX) transcription factor family member identified in silico on chromosome Xp11.21 in humans. FOXR2 is an ortholog of FOXR1, and the encoded proteins are 57.7% identical 69 . FOXR1 is a transcriptional inhibitor of FOX family target genes such as Cdkn1b (p27Kip1) 70 . Similar to Foxr1, Foxr2 is expressed in mouse embryonic development on embryonic day (E) 9.5, with reduced expression in adult tissues 69 . Examination of the Human Protein Atlas and Oncomine databases indicates that FOXR2 expression is low and variegated in normal adult human tissues, but expression is higher at the genomic (CNA gains) and protein levels in several cancers [71] [72] [73] . COSMIC-v63 reports 18 point mutations in FOXR2 from 4,862 samples 55 . We used the MutationAssessor program to determine the functional impact of the 18 point mutations on cancer, which ranged from neutral to medium functional impact, with 4 point mutations identified that affect the forkhead DNA-binding domain ( Supplementary  Table 11 ). These predictions may indicate that FOXR2 mutations are not as pivotal to cancer formation as is increased expression. Our comparative genomic analysis and functional data predict that FOXR2 is a proto-oncogene in human MPNST maintenance. FOX superfamily members have been implicated in human cancers through mechanisms such as gene amplifications and translocations 74 . Further studies are warranted to determine the extent of FOXR2 involvement in tumor development and its function in normal somatic cells.
Notably, in the grade 3 PNSTs containing T2/Onc-Foxr2 fusion transcripts, we observed splicing to the first annotated exon of Foxr2, where splice-acceptor elements were not previously described (Fig. 5) . We identified RNA splicing elements (a branch-point A, polypyrimidine tract and AG boundary) within 35 nucleotides of the first annotated Foxr2 exon, indicating the potential for splicing. Furthermore, full-length FOXR2 cDNA unexpectedly encodes two unique protein isoforms (Fig. 7b,d) , and we observed a bias in isoform loss after TALEN-mediated knockout (Fig. 7d) . The FOXR2 locus encodes five in-frame methionine residues at amino acid positions 1, 25, 53, 58 and 81 (four of which have optimal Kozak sequences), with the predicted npg proteins having molecular weights of 35.93 kDa, 32.94 kDa, 29.76 kDa, 29.17 kDa and 26.81 kDa. Further studies are necessary to define the FOXR2 locus in mice and humans and to determine the implications of the use of the alternative start codons in tumorigenesis.
Overall, using an SB forward genetic screen, we identified hundreds of candidate cancer driver genes that promote Schwann cell tumorigenesis. Moreover, we determined a new functional role for the novel proto-oncogene FOXR2 in human MPNST maintenance. Note: Supplementary information is available in the online version of the paper.
